{"hands_on_practices": [{"introduction": "Accurate antibiotic dosing is a cornerstone of safe dental practice, particularly when providing prophylaxis against infective endocarditis (IE). This practice problem focuses on applying established clinical guidelines from the American Heart Association (AHA) and American Dental Association (ADA) to a realistic clinical schedule. By working through this scenario, you will sharpen essential skills in calculating doses for both adult and pediatric patients, including critical considerations like weight-based adjustments, dose capping, and selecting appropriate alternatives for patients with allergies [@problem_id:4692907].", "problem": "A stomatology clinic plans a day of procedures that meet criteria for Infective Endocarditis (IE) prophylaxis according to current American Heart Association (AHA) and American Dental Association (ADA) guidance. Prophylaxis is administered as a single pre-procedure oral loading dose given $30$–$60$ minutes prior to instrumentation that is expected to cause gingival manipulation or mucosal bleeding. For patients without penicillin allergy, the standard regimen is amoxicillin, adult dose $2\\,\\mathrm{g}$, and pediatric dose $50\\,\\mathrm{mg}/\\mathrm{kg}$, with a maximum single dose capped at the adult maximum of $2\\,\\mathrm{g}$. The clinic has a safety policy that excludes clindamycin because of unfavorable risk–benefit considerations. For patients with immediate-type penicillin allergy, the clinic selects a macrolide alternative consistent with AHA/ADA guidance. Use azithromycin with adult dose $500\\,\\mathrm{mg}$ and pediatric dose $15\\,\\mathrm{mg}/\\mathrm{kg}$, capped at a maximum single dose of $500\\,\\mathrm{mg}$.\n\nOn a given day, the schedule includes:\n- $5$ non-allergic adults requiring prophylaxis.\n- $2$ non-allergic pediatric patients with body weights $18\\,\\mathrm{kg}$ and $42\\,\\mathrm{kg}$.\n- $2$ penicillin-allergic adults with immediate-type (anaphylactic) reactions.\n- $3$ penicillin-allergic pediatric patients with body weights $20\\,\\mathrm{kg}$, $35\\,\\mathrm{kg}$, and $55\\,\\mathrm{kg}$.\n\nUsing only the dosing facts stated above, compute the total mass of antibiotic that must be dispensed for that day when the appropriate regimen is given to each patient group. Express the final total in grams and round your answer to four significant figures. Do not include the unit in your final boxed answer.", "solution": "The problem statement is evaluated and found to be valid. It is scientifically grounded in established clinical pharmacology and dental practice guidelines, is quantitatively well-posed with all necessary information provided for a unique solution, and is expressed in objective, unambiguous language. We may therefore proceed with the calculation.\n\nThe objective is to compute the total mass of antibiotic dispensed, which is the sum of the total mass of amoxicillin ($M_{amox}$) and the total mass of azithromycin ($M_{azithro}$).\n$$M_{total} = M_{amox} + M_{azithro}$$\nWe will calculate each component separately, ensuring all masses are expressed in grams ($\\mathrm{g}$).\n\nFirst, we calculate the total mass of amoxicillin ($M_{amox}$) for patients without a penicillin allergy.\n\n1.  **Non-allergic adults:**\n    There are $5$ non-allergic adults, each receiving a standard dose of $2\\,\\mathrm{g}$.\n    $$M_{amox, adults} = 5 \\times 2\\,\\mathrm{g} = 10\\,\\mathrm{g}$$\n\n2.  **Non-allergic pediatric patients:**\n    The pediatric dose is $50\\,\\mathrm{mg}/\\mathrm{kg}$, with a maximum cap of $2\\,\\mathrm{g}$, which is equivalent to $2000\\,\\mathrm{mg}$. The dose $d_{amox}(w)$ for a patient with body weight $w$ is given by:\n    $$d_{amox}(w) = \\min(w \\times 50\\,\\mathrm{mg}/\\mathrm{kg}, 2000\\,\\mathrm{mg})$$\n\n    -   For the patient with weight $w_1 = 18\\,\\mathrm{kg}$:\n        The calculated dose is $18\\,\\mathrm{kg} \\times 50\\,\\mathrm{mg}/\\mathrm{kg} = 900\\,\\mathrm{mg}$. Since $900\\,\\mathrm{mg} < 2000\\,\\mathrm{mg}$, the dose is $900\\,\\mathrm{mg}$.\n        $$d_1 = 900\\,\\mathrm{mg} = 0.9\\,\\mathrm{g}$$\n    -   For the patient with weight $w_2 = 42\\,\\mathrm{kg}$:\n        The calculated dose is $42\\,\\mathrm{kg} \\times 50\\,\\mathrm{mg}/\\mathrm{kg} = 2100\\,\\mathrm{mg}$. Since $2100\\,\\mathrm{mg} > 2000\\,\\mathrm{mg}$, the dose is capped at the maximum.\n        $$d_2 = 2000\\,\\mathrm{mg} = 2.0\\,\\mathrm{g}$$\n\n    The total mass of amoxicillin for pediatric patients is the sum of these individual doses:\n    $$M_{amox, peds} = d_1 + d_2 = 0.9\\,\\mathrm{g} + 2.0\\,\\mathrm{g} = 2.9\\,\\mathrm{g}$$\n\nThe total mass of amoxicillin is the sum of the adult and pediatric masses:\n$$M_{amox} = M_{amox, adults} + M_{amox, peds} = 10\\,\\mathrm{g} + 2.9\\,\\mathrm{g} = 12.9\\,\\mathrm{g}$$\n\nNext, we calculate the total mass of azithromycin ($M_{azithro}$) for patients with a penicillin allergy.\n\n1.  **Penicillin-allergic adults:**\n    There are $2$ penicillin-allergic adults, each receiving a standard dose of $500\\,\\mathrm{mg}$.\n    $$M_{azithro, adults} = 2 \\times 500\\,\\mathrm{mg} = 1000\\,\\mathrm{mg} = 1.0\\,\\mathrm{g}$$\n\n2.  **Penicillin-allergic pediatric patients:**\n    The pediatric dose is $15\\,\\mathrm{mg}/\\mathrm{kg}$, with a maximum cap of $500\\,\\mathrm{mg}$. The dose $d_{azithro}(w)$ for a patient with body weight $w$ is:\n    $$d_{azithro}(w) = \\min(w \\times 15\\,\\mathrm{mg}/\\mathrm{kg}, 500\\,\\mathrm{mg})$$\n\n    -   For the patient with weight $w_3 = 20\\,\\mathrm{kg}$:\n        The calculated dose is $20\\,\\mathrm{kg} \\times 15\\,\\mathrm{mg}/\\mathrm{kg} = 300\\,\\mathrm{mg}$. Since $300\\,\\mathrm{mg} < 500\\,\\mathrm{mg}$, the dose is $300\\,\\mathrm{mg}$.\n        $$d_3 = 300\\,\\mathrm{mg} = 0.3\\,\\mathrm{g}$$\n    -   For the patient with weight $w_4 = 35\\,\\mathrm{kg}$:\n        The calculated dose is $35\\,\\mathrm{kg} \\times 15\\,\\mathrm{mg}/\\mathrm{kg} = 525\\,\\mathrm{mg}$. Since $525\\,\\mathrm{mg} > 500\\,\\mathrm{mg}$, the dose is capped at the maximum.\n        $$d_4 = 500\\,\\mathrm{mg} = 0.5\\,\\mathrm{g}$$\n    -   For the patient with weight $w_5 = 55\\,\\mathrm{kg}$:\n        The calculated dose is $55\\,\\mathrm{kg} \\times 15\\,\\mathrm{mg}/\\mathrm{kg} = 825\\,\\mathrm{mg}$. Since $825\\,\\mathrm{mg} > 500\\,\\mathrm{mg}$, the dose is capped at the maximum.\n        $$d_5 = 500\\,\\mathrm{mg} = 0.5\\,\\mathrm{g}$$\n\n    The total mass of azithromycin for pediatric patients is the sum of these individual doses:\n    $$M_{azithro, peds} = d_3 + d_4 + d_5 = 0.3\\,\\mathrm{g} + 0.5\\,\\mathrm{g} + 0.5\\,\\mathrm{g} = 1.3\\,\\mathrm{g}$$\n\nThe total mass of azithromycin is the sum of the adult and pediatric masses:\n$$M_{azithro} = M_{azithro, adults} + M_{azithro, peds} = 1.0\\,\\mathrm{g} + 1.3\\,\\mathrm{g} = 2.3\\,\\mathrm{g}$$\n\nFinally, the total mass of all antibiotics dispensed is the sum of the total masses of amoxicillin and azithromycin.\n$$M_{total} = M_{amox} + M_{azithro} = 12.9\\,\\mathrm{g} + 2.3\\,\\mathrm{g} = 15.2\\,\\mathrm{g}$$\n\nThe problem requires the answer to be expressed in grams and rounded to four significant figures. The calculated value $15.2$ is expressed as $15.20$ to meet this requirement.", "answer": "$$\n\\boxed{15.20}\n$$", "id": "4692907"}, {"introduction": "Administering medications to patients with organ impairment requires careful dose adjustment to prevent toxicity while maintaining therapeutic efficacy. This exercise explores the crucial clinical scenario of adjusting an antiviral agent, acyclovir, for a patient with reduced renal function. Using the principle of proportional scaling, you will learn how to modify a dosing regimen to account for changes in drug clearance, ensuring that the patient's average drug exposure remains equivalent to that of a patient with normal renal function, thereby minimizing the risk of adverse effects like neurotoxicity [@problem_id:4692848].", "problem": "A $62$-year-old man with severe primary Herpes Simplex Virus (HSV) gingivostomatitis is admitted to an oral and maxillofacial surgery service and started on intravenous (IV) acyclovir. The standard regimen for normal renal function is acyclovir $5$ mg/kg IV every $8$ hours. His creatinine clearance (CrCl) is measured at $30$ mL/min. To minimize the risk of acyclovir-associated neurotoxicity, the clinical goal is to maintain the same average steady-state exposure as in a patient with normal renal function by adjusting the maintenance regimen using first-principles pharmacokinetics.\n\nAssume the following foundational facts:\n- Acyclovir exhibits linear pharmacokinetics at therapeutic doses.\n- Renal elimination accounts for essentially all systemic clearance under these conditions, and acyclovir clearance is proportional to creatinine clearance.\n- The labeled regimen is intended for a reference creatinine clearance of $90$ mL/min.\n- The volume of distribution and single-dose amount per administration will be held constant; only the dosing interval will be adjusted.\n\nUsing proportional scaling of the dosing interval to renal clearance so as to preserve average steady-state exposure and thereby avoid neurotoxicity, compute the adjusted dosing interval. Express your final answer in hours and round to three significant figures.", "solution": "The problem requires calculating an adjusted dosing interval for acyclovir in a patient with renal impairment to maintain the same average drug exposure as a patient with normal renal function. The solution uses the principle of proportional scaling based on creatinine clearance.\n\nThe average steady-state concentration ($C_{\\text{ss,avg}}$) for a drug given at a dose ($D$) over a dosing interval ($\\tau$) is determined by the drug's clearance ($\\text{CL}$):\n$$ C_{\\text{ss,avg}} = \\frac{D / \\tau}{\\text{CL}} = \\frac{D}{\\text{CL} \\cdot \\tau} $$\nTo maintain the same average exposure in the adjusted regimen (adj) as in the normal regimen (norm), we set their average steady-state concentrations equal:\n$$ (C_{\\text{ss,avg}})_{\\text{adj}} = (C_{\\text{ss,avg}})_{\\text{norm}} $$\n$$ \\frac{D_{\\text{adj}}}{\\text{CL}_{\\text{adj}} \\cdot \\tau_{\\text{adj}}} = \\frac{D_{\\text{norm}}}{\\text{CL}_{\\text{norm}} \\cdot \\tau_{\\text{norm}}} $$\nThe problem states that the dose per administration is held constant ($D_{\\text{adj}} = D_{\\text{norm}}$), so the equation simplifies to:\n$$ \\text{CL}_{\\text{adj}} \\cdot \\tau_{\\text{adj}} = \\text{CL}_{\\text{norm}} \\cdot \\tau_{\\text{norm}} $$\nSolving for the adjusted interval, $\\tau_{\\text{adj}}$:\n$$ \\tau_{\\text{adj}} = \\tau_{\\text{norm}} \\cdot \\frac{\\text{CL}_{\\text{norm}}}{\\text{CL}_{\\text{adj}}} $$\nThis shows that the dosing interval should be lengthened in inverse proportion to the reduction in clearance.\n\nThe problem states that acyclovir clearance is proportional to creatinine clearance ($\\text{CL} \\propto \\text{CrCl}$). Therefore, the ratio of drug clearances is equal to the ratio of creatinine clearances:\n$$ \\frac{\\text{CL}_{\\text{norm}}}{\\text{CL}_{\\text{adj}}} = \\frac{\\text{CrCl}_{\\text{norm}}}{\\text{CrCl}_{\\text{adj}}} $$\nSubstituting this into the equation for $\\tau_{\\text{adj}}$:\n$$ \\tau_{\\text{adj}} = \\tau_{\\text{norm}} \\cdot \\frac{\\text{CrCl}_{\\text{norm}}}{\\text{CrCl}_{\\text{adj}}} $$\nNow, we insert the given values:\n- Standard interval, $\\tau_{\\text{norm}} = 8$ hours\n- Normal creatinine clearance, $\\text{CrCl}_{\\text{norm}} = 90$ mL/min\n- Patient's creatinine clearance, $\\text{CrCl}_{\\text{adj}} = 30$ mL/min\n\n$$ \\tau_{\\text{adj}} = 8 \\text{ hours} \\times \\frac{90 \\text{ mL/min}}{30 \\text{ mL/min}} = 8 \\text{ hours} \\times 3 = 24 \\text{ hours} $$\nThe problem asks for the answer rounded to three significant figures, which is $24.0$.", "answer": "$$ \\boxed{24.0} $$", "id": "4692848"}, {"introduction": "Effective management of severe odontogenic infections often requires moving beyond standard dosing to regimens tailored to pharmacokinetic (PK) and pharmacodynamic (PD) targets. This advanced problem challenges you to design a metronidazole regimen for necrotizing ulcerative gingivitis from first principles. You will integrate concepts such as volume of distribution, drug clearance, and half-life to calculate a dose that achieves a specific PD target—the free-drug Area Under the Curve to MIC ratio ($f\\text{AUC}/\\text{MIC}$), a key predictor of antimicrobial success—thereby linking fundamental theory to sophisticated clinical decision-making [@problem_id:4692918].", "problem": "A 70-kilogram adult presents with necrotizing ulcerative gingivitis requiring systemic antibiotic therapy. Metronidazole is selected due to its activity against obligate anaerobes prevalent in intraoral necrotizing infections. For this patient, assume a one-compartment, linear, time-invariant pharmacokinetic model with first-order elimination and the following properties: oral bioavailability $F=1$, elimination half-life $t_{1/2}=8$ hours, apparent volume of distribution per kilogram $V_{d,\\text{kg}}=0.6$ liters per kilogram, and unbound fraction in plasma $f_u=0.8$. The Minimum Inhibitory Concentration (MIC) for the dominant anaerobic pathogen is $0.75$ milligrams per liter. The pharmacodynamic objective is a conservative free-drug Area Under the plasma Concentration–time curve to MIC ratio over $24$ hours satisfying\n$$\\frac{f\\text{AUC}_{0-24}}{\\text{MIC}} \\geq 200,$$\nto ensure adequate sterilization of necrotic periodontal tissues under the constraints of interpatient variability and severe local burden.\n\nUsing only first principles of one-compartment pharmacokinetics and linear superposition, determine the minimal metronidazole per-dose amount $D$ (in milligrams) given every $\\tau=8$ hours that attains the pharmacodynamic objective. Then, select the nearest practical tablet strength consistent with standard availability and use that rounded regimen to calculate the total exposure $\\text{AUC}_{0-168}$ captured within the $7$-day treatment window from $t=0$ to $t=168$ hours for this thrice-daily schedule starting at $t=0$ hours, assuming immediate absorption after each dose and no missed doses. Express the total exposure in milligram·hour per liter, and round the total exposure to four significant figures. Your final answer must be given as a row vector $\\begin{pmatrix}D & \\text{AUC}_{0-168}\\end{pmatrix}$, where $D$ is the selected per-dose amount in milligrams and $\\text{AUC}_{0-168}$ is the $7$-day total exposure in milligram·hour per liter, with no units included inside the vector.", "solution": "The problem requires the determination of a metronidazole dosing regimen and the subsequent calculation of total drug exposure over a $7$-day period. The solution proceeds by first validating the problem statement and then applying first principles of one-compartment pharmacokinetics.\n\n### Problem Validation\n**Step 1: Extract Givens**\n- Patient mass, $m = 70 \\text{ kg}$\n- Pharmacokinetic model: One-compartment, linear, time-invariant, first-order elimination.\n- Oral bioavailability, $F = 1$\n- Elimination half-life, $t_{1/2} = 8 \\text{ h}$\n- Apparent volume of distribution per kilogram, $V_{d,\\text{kg}} = 0.6 \\text{ L/kg}$\n- Unbound fraction in plasma, $f_u = 0.8$\n- Minimum Inhibitory Concentration, $\\text{MIC} = 0.75 \\text{ mg/L}$\n- Pharmacodynamic objective: $\\frac{f\\text{AUC}_{0-24}}{\\text{MIC}} \\geq 200$\n- Dosing interval, $\\tau = 8 \\text{ h}$\n- Absorption: Immediate (modeled as an intravenous bolus).\n- Treatment duration: $t=0$ to $t=168 \\text{ h}$ ($7$ days).\n- Initial dose: At $t=0$.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, using standard pharmacokinetic models and parameters for metronidazole that are clinically realistic. It is well-posed, providing all necessary information to determine a unique solution for the requested quantities. The language is objective and formal. The problem does not violate any of the invalidity criteria.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A solution will be derived.\n\n### Derivation of Solution\n\n**1. Calculation of Pharmacokinetic Parameters**\nFirst, we calculate the patient-specific primary pharmacokinetic parameters: the apparent volume of distribution ($V_d$) and the systemic clearance ($\\text{CL}$).\n\nThe total apparent volume of distribution is calculated from the per-kilogram value and the patient's mass:\n$$V_d = V_{d,\\text{kg}} \\times m = (0.6 \\text{ L/kg}) \\times (70 \\text{ kg}) = 42 \\text{ L}$$\n\nThe first-order elimination rate constant, $k_e$, is determined from the elimination half-life, $t_{1/2}$:\n$$k_e = \\frac{\\ln(2)}{t_{1/2}} = \\frac{\\ln(2)}{8 \\text{ h}}$$\n\nSystemic clearance, $\\text{CL}$, is the product of the elimination rate constant and the volume of distribution:\n$$\\text{CL} = k_e \\times V_d = \\left(\\frac{\\ln(2)}{8 \\text{ h}}\\right) \\times (42 \\text{ L}) = 5.25 \\ln(2) \\text{ L/h}$$\n\n**2. Determination of the Minimal Dose**\nThe pharmacodynamic (PD) target is given as $\\frac{f\\text{AUC}_{0-24}}{\\text{MIC}} \\geq 200$, where $f\\text{AUC}_{0-24}$ is the free-drug Area Under the Curve over a $24$-hour period. This target is conventionally assessed at steady state, representing the sustained therapeutic effect. The notation $\\text{AUC}_{0-24}$ at steady state refers to the total exposure over a $24$-hour interval.\n\nAt steady state, the AUC over a single dosing interval, $\\tau$, is given by:\n$$\\text{AUC}_{\\tau, \\text{ss}} = \\frac{F \\cdot D}{\\text{CL}}$$\nwhere $D$ is the dose administered every $\\tau$ hours.\n\nSince the dosing interval is $\\tau=8$ hours, a $24$-hour period comprises three such intervals. The total AUC over $24$ hours at steady state is:\n$$\\text{AUC}_{0-24, \\text{ss}} = 3 \\times \\text{AUC}_{\\tau, \\text{ss}} = 3 \\frac{F \\cdot D}{\\text{CL}}$$\n\nThe free-drug AUC is $f_u \\times \\text{AUC}_{0-24, \\text{ss}}$. Substituting this into the PD target inequality:\n$$\\frac{f_u \\cdot \\left(3 \\frac{F \\cdot D}{\\text{CL}}\\right)}{\\text{MIC}} \\geq 200$$\n\nWe solve for the minimal dose, $D_{\\text{min}}$, by setting the expression to equality and rearranging:\n$$D \\geq \\frac{200 \\cdot \\text{MIC} \\cdot \\text{CL}}{3 \\cdot f_u \\cdot F}$$\n\nSubstituting the known values:\n$$D \\geq \\frac{200 \\cdot (0.75 \\text{ mg/L}) \\cdot (5.25 \\ln(2) \\text{ L/h})}{3 \\cdot (0.8) \\cdot 1}$$\n$$D \\geq \\frac{150 \\cdot 5.25 \\ln(2)}{2.4} \\text{ mg} = \\frac{787.5 \\ln(2)}{2.4} \\text{ mg} = 328.125 \\ln(2) \\text{ mg}$$\n$$D \\geq 227.422... \\text{ mg}$$\n\nStandard tablet strengths for metronidazole include $250$ mg and $500$ mg. To satisfy the condition $D \\geq 227.422 \\text{ mg}$, the nearest practical and sufficient dose is $250$ mg.\nTherefore, we select the per-dose amount $D = 250 \\text{ mg}$.\n\n**3. Calculation of Total Exposure $\\text{AUC}_{0-168}$**\nThe chosen regimen is $D = 250$ mg every $\\tau = 8$ hours. The treatment duration is $168$ hours. The number of dosing intervals is $N = \\frac{168 \\text{ h}}{8 \\text{ h}} = 21$.\n\nThe total exposure, $\\text{AUC}_{0-168}$, is the sum of the AUCs over the $21$ dosing intervals from $t=0$ to $t=168$. The AUC in the $n$-th dosing interval (from $t=(n-1)\\tau$ to $t=n\\tau$) is given by:\n$$\\text{AUC}_{(n-1)\\tau \\to n\\tau} = \\frac{D}{\\text{CL}}(1-R^n)$$\nwhere $R$ is the accumulation factor, $R = \\exp(-k_e \\tau)$.\n\nGiven $t_{1/2} = 8$ h and $\\tau=8$ h, we have $k_e \\tau = \\frac{\\ln(2)}{8} \\times 8 = \\ln(2)$.\n$$R = \\exp(-\\ln(2)) = 0.5$$\n\nThe total AUC is the sum over all $N=21$ intervals:\n$$\\text{AUC}_{0-168} = \\sum_{n=1}^{21} \\text{AUC}_{(n-1)\\tau \\to n\\tau} = \\sum_{n=1}^{21} \\frac{D}{\\text{CL}}(1-R^n)$$\n$$\\text{AUC}_{0-168} = \\frac{D}{\\text{CL}} \\left( \\sum_{n=1}^{21} 1 - \\sum_{n=1}^{21} R^n \\right) = \\frac{D}{\\text{CL}} \\left( N - \\sum_{n=1}^{21} R^n \\right)$$\nThe second sum is a geometric series:\n$$\\sum_{n=1}^{21} R^n = \\frac{R(1-R^{N})}{1-R} = \\frac{0.5(1-0.5^{21})}{1-0.5} = 1 - 0.5^{21}$$\nSubstituting this back into the expression for total AUC:\n$$\\text{AUC}_{0-168} = \\frac{D}{\\text{CL}} \\left( 21 - (1 - 0.5^{21}) \\right) = \\frac{D}{\\text{CL}} \\left( 20 + 0.5^{21} \\right)$$\n\nNow, we compute the numerical value using $D = 250 \\text{ mg}$ and $\\text{CL} = 5.25 \\ln(2) \\text{ L/h}$:\n$$\\text{AUC}_{0-168} = \\frac{250 \\text{ mg}}{5.25 \\ln(2) \\text{ L/h}} \\left( 20 + \\left(\\frac{1}{2}\\right)^{21} \\right)$$\n$$\\text{AUC}_{0-168} = \\frac{250}{5.25 \\ln(2)} \\left( 20 + \\frac{1}{2097152} \\right) \\text{ mg}\\cdot\\text{h/L}$$\n$$\\text{AUC}_{0-168} \\approx (68.708304) \\times (20.0000004768) \\text{ mg}\\cdot\\text{h/L}$$\n$$\\text{AUC}_{0-168} \\approx 1374.16609 \\text{ mg}\\cdot\\text{h/L}$$\n\nRounding the total exposure to four significant figures, we get:\n$$\\text{AUC}_{0-168} \\approx 1374 \\text{ mg}\\cdot\\text{h/L}$$\n\nThe final answer components are the selected dose $D=250$ mg and the calculated total exposure $\\text{AUC}_{0-168}=1374$ mg·h/L.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n250 & 1374\n\\end{pmatrix}\n}\n$$", "id": "4692918"}]}